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South Africa (SA) has the world’s highest HIV burden, with 7.52 
million people (13.1% of the world’s HIV population) living with 
HIV. However, AIDS-related deaths and new HIV infections have 
both been reduced by approximately half since 2004.[1] A national 
antiretroviral therapy (ART) programme provides free medication 
to ~4.4 million people living with HIV.[2] The goals of ART are to 
prolong life expectancy, decrease opportunistic illnesses and improve 
quality of life, while also preventing transmission of the virus. These 
goals are achieved by suppressing the HIV viral load (VL), allowing 
restoration of immune function, as measured partly by increasing 
CD4+ cell counts.[3,4]
Since 2012, all HIV-positive patients in SA have commenced 
treatment with a preferred first-line fixed-dose combination regimen 
of efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC).[5-7] This 
treatment regimen is favoured because of its tolerability, simplicity 
and cost-effectiveness, but it provides a low barrier for resistance, 
which results in treatment failure for a proportion of patients.[8] 
Patients who experience virological failure (VL ≥1 000 copies/mL) 
on at least two occasions 2 months apart are offered second-line 
treatment containing protease inhibitors (PIs), in accordance with 
local guidelines.[7] Although the exact transfer rates are unknown, 
it is estimated that there are almost 200  000 second-line patients 
in SA.[5,9]
This progression from first- to second-line treatment is in 
accordance with World Health Organization (WHO) guidelines. [10] 
Up to 30% of second-line patients still experience virological 
failure in some SA cohorts.[11] Second-line treatment is complex, 
involving numerous tablets with substantial toxicity and twice-daily 
dosing. However, there are limited studies that explore second-line 
treatment outcomes.[8,12,13] Little is known about the long-term 
clinical outcomes of second-line patients. This study followed a 
large second-line cohort in Johannesburg, while also identifying 
demographic characteristics and laboratory and clinical factors 
that predict virological failure, which may allow for future targeted 
adherence and support interventions.
Methods
Study design
This retrospective cohort study used the TIER.Net database for 
secondary data on adult second-line patients. TIER.Net is the 
ART monitoring and evaluation system used by the SA National 
Department of Health for recording HIV, pre-ART, ART and 
tuberculosis (TB) patient-level information including HIV diagnosis 
dates, HIV results, ART start dates, ART switch dates, HIV/TB 
co-infection, treatment retention, VL and CD4+ cell count results. 
Second-line patients were defined as patients who experienced 
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virological failure (VL ≥1 000 copies/mL) 
on at least two occasions 2 months apart and 
were then switched to a PI-based regimen.
Setting
Records were reviewed for all ART patients 
from eight public health facilities in central 
Johannesburg (subdistrict F). The facilities 
were two hospitals, one community health 
centre (CHC) and five primary healthcare 
clinics.
Data collection
The total cohort of 825 represented all 
patients from the facilities who initiated their 
second-line treatment between 1 January 
2014 and 31 December 2015. This cut-off 
period was chosen to give the cohort patients 
a minimum of 1 year to receive their annual 
standard-of-care VL test. In order to isolate 
this cohort, data were extracted from the 
TIER.Net database for all patients active on 
ART (N=56  894). A total of 53  287 patients 
on first-line treatment were then excluded, 
leaving a total of 3 607 active patients on 
second-line treatment. Of these second-line 
patients, 2  781 were excluded because they 
initiated their second-line treatment before 
1 January 2014. Of the remaining 826 patients 
who met the inclusion criteria, one had 
missing information and was omitted, and 
the remaining 825 were followed until data 
collection ended in July 2017. The participant 
flow diagram is shown in Fig. 1.
All data were exported from TIER.Net 
to Excel 2016 Professional Plus (Microsoft, 
USA), where data were cleaned and formatted. 
The following variables were extracted for 
further analysis: treatment facility, gender, 
date of birth, age at ART switch, ART start 
date, second-line treatment start date, baseline 
ART regimen, baseline CD4+ cell count at 
start of ART, most recent CD4+ cell count 
(after ART switch), most recent VL (after 
ART switch), and retention-in-care status.
CD4+ cell counts were presented in four 
ranges for values ≤500 cells/µL and as a single 
category for all values >500 cells/µL. Since this 
cohort started ART before 2017, the CD4+ 
cell count disaggregation reported here was 
guided by the WHO guidelines. [14-16] VL was 
categorised into suppressed or unsuppressed 
based on the WHO threshold for suppression 
of <1 000  copies/mL.[7,17] Retention-in-care 
status was assessed as at 31 July 2017, and 
categorised into active in care (AIC), lost to 
follow-up (LTFU), transferred out (moved 
outside a facility included in the analysis), or 
known to be dead.
The datasets analysed during the study 
are available from the corresponding author 
(SBG) on reasonable request.
Data analysis
Data from the Excel spreadsheets were 
exported to Stata version 15.1 (StataCorp, 
USA) for analysis. Continuous data 
were summarised using medians (and 
interquartile ranges where appropriate) 
and then grouped into categories to 
define demographic characteristics. Three 
outcome variables, CD4+ cell count 
levels, VL and retention-in-care status, 
were quantified at the cohort level, then 
analysed further to identify associations 
between outcome variables and selected 
demographic characteristics with Pearson’s 
χ2 tests. Furthermore, multiple logistic 
regression models were built for the 
outcome variables to identify independent 
predictors. These predictors were reported 
as unadjusted and adjusted odds ratios 
(ORs), with 95% confidence intervals 
(CIs) and p-values; p<0.05 was considered 
significant. Survival analysis (for the LTFU 
category) was conducted using the Kaplan-
Meier estimator to understand the pattern 
of attrition.
Ethical considerations
Ethical clearance was received from the 
University of the Witwatersrand Human 
Research Ethics Committee (ref. no. 
M170691). In addition, approval was 
granted by the Johannesburg Health 
District (ref. no. 2017-08-003) and the 
National Health Research Database (ref. no. 
GP_201708_030).
Results
Demographic profile (Table 1)
At the start of first-line ART, the cohort 
had an average baseline CD4+ count of 
109 cells/µL, and 59.9% of the patients 
were female. The median age at the start 
of second-line treatment was 37 years, 
the median duration of first-line ART 
was 63 months, and patients switched 
from first-line to second-line treatment 
after 38 months on average. Zidovudine/
lamivudine/lopinavir/ritonavir (AZT/3TC/
LPV/r) was the most common second-line 
antiretroviral, with 68.0% of the cohort on 
this combination. The other 32.0% were on 
tenofovir/lamivudine/lopinavir/ritonavir 
(TDF/3TC/LPV/r).
For the cohort, a single site (Hillbrow 
CHC) provided 352 (42.7%) of patients, while 
Charlotte Maxeke Johannesburg Academic 
Hospital, South Rand Hospital and Yeoville 
Clinic were the only other facilities that 
provided more than 100  patients. Just under 
half of the patients had been transferred 
to their current treatment facilities from 
outside subdistrict F, while the other 56.9% 
were new patients who had commenced 
treatment in subdistrict F.
Active ART patients
N=56 894
First-line treatment
n=53 287
Missing information
n=1
Second-line cohort with
complete records
n=825
Second-line treatment
n=3 607
Initiated second-line treatment 
before 1 January 2014
n=2 781
Initiated second-line treatment between 
1 January 2014 and 31 December 2015
n=826
Fig. 1. Second-line cohort flow diagram. (ART = antiretroviral therapy.)
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Outcome variables
A summary of the cohort outcome variables is set out in Table 2. 
In order to evaluate predictors for the three outcome variables, 
CD4+ cell count, VL and retention-in-care status, correlations were 
explored with different demographic characteristics.
Gender, new v. transferred-in patients, total duration of ART, 
second-line regimen, baseline CD4+ cell count at ART start and most 
recent VL were all correlated with the CD4+ cell count outcome. Age 
at ART switch, gender, new v. transferred-in patients (patients who 
were now on second-line treatment in subdistrict F, but started their 
initial treatment in a different region) and most recent CD4+ cell 
count were all correlated with VL outcomes, while facility, duration 
of ART, baseline CD4+ cell count at start of ART and most recent 
VL were all significantly correlated with retention-in-care status 
outcomes. The Pearson’s χ2 values are presented in Table 3, and to 
ensure that there were no affirmative confounders, all variables 
underwent further logistical analysis with ORs and adjusted ORs. 
One affirmative confounder was identified (age at ART switch and 
retention-in-care status) and added to the statistically significant 
correlations, which are presented in Table 4.
CD4+ cell count
For the cohort, the most recent median CD4+ cell count was 
286 cells/µL, which represented a 177 cells/µL (270%) increase from 
the 109 cells/µL baseline count at the start of ART. Of the patients, 
132 (22.5%) achieved healthy CD4+ cell counts >500 cells/µL, 
whereas only 22 (3.1%) were above this threshold with their baseline 
CD4+ cell counts.
Males (OR 0.53, 95% CI 0.32 - 0.88) and patients transferred in to 
their current ART facility (OR 0.54, 95% CI 0.33 - 0.88) were both less 
likely to have a CD4+ cell count >500 cells/µL at last measurement 
than females and new patients, respectively. Patients taking AZT/3TC/
LPV/r as their regimen were also less likely (OR 0.42, 95% CI 0.26 - 
0.69) to have a CD4+ cell count >500 cells/µL than patients taking 
Table 1. Demographic characteristics
Age at start of second-line treatment (years) (N=825), median (IQR) 37 (33 - 43)
Duration of ART since starting first-line treatment (months) (N=825), median (IQR) 63 (25 - 94)
Time to switch from first- to second-line treatment (months) (N=745), median (IQR) 38 (19 - 67)
Baseline CD4+ cell count at start of ART (cells/µL) (N=705), median (IQR) 109 (42 - 204)
Facility (N=825), n (%)
80 Albert Street Clinic 18 (2.2)
Charlotte Maxeke Hospital 116 (14.1)
Hillbrow CHC 352 (42.7)
Jeppe Clinic 47 (5.7)
Joubert Park Clinic 30 (3.6)
Malvern Clinic 16 (1.9)
Rosettenville Clinic 10 (1.2)
South Rand Hospital 122 (14.8)
Yeoville Clinic 114 (13.8)
Age at ART switch (years) (N=825), n (%)
<25 25 (3.0)
25 - 34 251 (30.4)
35 - 49 466 (56.5)
≥50 83 (10.1)
Gender (N=825), n (%)
Female 494 (59.9)
Male 331 (40.1)
New patients and transfers in (N=825), n (%)
New patients 470 (56.9)
Transferred-in patients 355 (43.0)
Total duration of ART (years) (N=825), n (%)
1 - 4 247 (29.9)
5 - 9 474 (57.5)
≥10 104 (12.6)
Prescribed second-line treatment (N=825), n (%)
TDF/3TC/LPV/r 264 (32.0)
AZT/3TC/LPV/r 561 (68.0)
Baseline CD4+ cell count (cells/µL) at start of ART (N=705), n (%)
<100 330 (46.9)
101 - 200 192 (27.2)
201 - 350 127 (18.0)
351 - 500 34 (4.8)
>500 22 (3.1)
IQR = interquartile range; ART = antiretroviral therapy; CHC = community health centre; TDF/3TC/LPV/r = tenofovir/lamivudine/lopinavir/ritonavir;  
AZT/3TC/LPV/r = zidovudine/lamivudine/lopinavir/ritonavir.
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TDF/3TC/LPV/r. Patients who had been on 
ART for at least 10 years were more likely to 
achieve CD4+ cell counts >500 cells/µL than 
patients who had been on ART for ≤4 years, 
with an OR of 3.23 (95% CI 1.51 - 6.91). 
Patients with virological failure on second-
line treatment (OR 0.15, 95% CI 0.052 - 0.42) 
were less likely to achieve CD4+ cell counts 
>500 cells/µL than virologically suppressed 
patients.
VL suppression
The average time (based on VL dates included 
in patient records) to VL measurement 
after ART switch was 20 months, and the 
most recent median VL was 124 copies/mL. 
A total of 570 patients (83.1%) achieved viral 
suppression based on the 1 000 copies/mL 
threshold.
VL suppression was less likely in male 
patients than in females (OR 0.54, 95% 
CI  0.36 - 0.81) and in patients transferred 
from ART facilities outside subdistrict F 
(OR 0.58, 95% CI 0.38 - 0.89). Suppression 
was also directly related to age at ART 
switch, with the oldest group (patients 
aged ≥50 years) far more likely to achieve 
viral suppression than the youngest group 
(<25 years) (OR 5.01, 95% CI 1.59 - 15.79).
Retention-in-care status
As a cohort, 597 patients (72.4%) remained 
AIC until data collection ended in July 2017. 
Of the outstanding patients, 161 (19.5%) 
were lost to follow-up, while 59 (7.2%) were 
transferred or moved out of subdistrict F, 
and 8 (1.0%) died. Total duration of ART 
was a significant predictor of retention-in-
care status, as patients on ART for 5 - 9 
years (OR 0.47, 95% CI 0.32 - 0.68) and 
>10 years (OR 0.54, 95% CI 0.30 - 0.96) 
were approximately twice as likely to 
remain AIC for the duration of the study 
as those on ART for <5 years. Age at ART 
switch showed that patients aged >50 years 
(OR 0.36, p=0.053) were most likely to be 
retained in care.
Three facilities, Hillbrow CHC (OR 0.27, 
95% CI 0.16 - 0.44), Jeppe Clinic (OR  0.38, 
95% CI 0.16 - 0.88) and South Rand Hospital 
(OR 0.24, 95% CI 0.12 - 0.47) were less 
likely than the others to have patients lost to 
follow-up. Patients with virological failure 
on second-line treatment were almost 
four times (OR 3.63, 95% CI 2.19 - 6.02) 
more likely to be lost to follow-up than 
virologically suppressed patients. Patients 
with baseline CD4+ cell counts between 351 
and 500 cells/µL at the start of ART were 
three times (OR  3.13, 95% CI  1.50 - 6.56) 
more likely to be lost to follow-up than 
patients with a CD4+ cell count <101 cells/
µL. No other baseline CD4+ cell count 
categories or most recent CD4+ cell counts 
were significant predictors of retention-in-
care status.
Survival analysis (Fig. 2) shows an 
expected decrease in patient retention in 
care. However, the drop becomes steadier 
from month 100 (just over 8 years on 
treatment) and declines sharply at month 
150 (12.5 years on treatment).
Table 2. Outcome variables
Most recent CD4+ cell count (cells/µL), median (IQR) 286 (160 - 478)
Most recent VL (copies/mL), median (IQR) 124 (46 - 639)
<1 000 124 (28 - 124)
≥1 000 36 612 (7 563 - 167 110)
Time to recorded VL after ART switch (months), median (IQR) 20 (14 - 28)
Most recent CD4+ cell count (cells/µL) (N=367), n (%)
<100 60 (16.3)
101 - 200 58 (15.8)
201 - 350 85 (23.2)
351 - 500 73 (19.9)
>500 91 (24.7)
Most recent VL (copies/mL) (N=686), n (%)
<1 000 570 (83.1)
≥1 000 116 (16.9)
Retention-in-care status (N=825), n (%)
AIC 597 (72.4)
LTFU 161 (19.5)
Transferred/moved out 59 (7.2)
Died 8 (1.0)
IQR = interquartile range; VL = viral load; ART = antiretroviral therapy; AIC = active in care; LTFU = lost to follow-up.
1
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Fig. 2. Retention-in-care estimates: loss to follow-up over time. (CI = confidence interval.)
923       December 2019, Vol. 109, No. 12
RESEARCH
Discussion
Global intentions for successful scaling up of ART include ensuring 
that 90% of all patients receiving WHO-endorsed ART are retained 
in care with suppressed VLs. [18] Switching treatment-failing patients 
from first-line to second-line regimens has been policy in the SA 
public health setting since inception of the ART programme in 
2004. [11] However, not much has been done to describe the long-
term clinical outcomes of second-line cohorts,[19] particularly in 
this setting, highlighting the value of our findings. Patients starting 
second-line treatment tended to have low CD4+ cell counts, but 
83.1% of our cohort showed viral suppression after switching from 
first-line treatment, demonstrating similar suppression rates to 
Table 3. Correlations between outcome variables and demographic characteristics
Most recent CD4+ cell count 
(cells/µL) Most recent VL (copies/mL) Retention-in-care status
≤500 (%) >500 (%) p-value (n) <1 000 (%) ≥1 000 (%) p-value (n) AIC LTFU p-value (n)
Age at ART switch (years) 0.147 (367) 0.020* (686) 0.180 (758)
<25 72.7 27.3 57.9 42.1 63.6 36.4
25 - 34 80.0 20.0 82.2 17.8 77.1 22.9
35 - 49 75.3 24.7 84.0 16.0 79.5 20.5
≥50 61.5 38.5 87.3 12.7 84.2 15.8
Gender 0.013* (367) 0.002* (686) 0.366 (758)
Female 70.4 29.6 86.7 13.3 80.4 19.6
Male 81.8 18.2 77.9 22.1 77.7 22.4
Facility 0.758 (367) 0.776 (683) <0.001* (770)
80 Albert Street Clinic 71.4 28.6 86.7 13.3 86.2 13.9
Charlotte Maxeke Hospital 74.0 26.0 79.8 20.2 100.0 0.0
Hillbrow CHC 74.8 25.2 85.9 14.1 63.4 36.6
Jeppe Clinic 66.7 33.3 86.1 13.9 81.8 18.2
Joubert Park Clinic 81.3 18.7 82.6 17.4 64.3 35.7
Malvern Clinic 62.5 37.5 87.5 12.5 87.5 12.5
Rosettenville Clinic 50.0 50.0 85.7 14.3 57.1 42.9
South Rand Hospital 78.5 21.5 78.4 21.6 87.5 12.5
Yeoville Clinic 79.2 20.8 82.1 17.8 61.2 38.8
New patients or transfers in 0.013* (367) 0.010* (683) 0.169 (758)
New 79.2 20.8 80.1 19.9 77.0 23.0
Transferred in 67.5 32.5 87.5 12.5 81.1 18.9
Total duration of ART (years) 0.007* (367) 0.140 (684) <0.001* (758)
1 - 4 80.8 19.2 80.2 19.8 68.5 31.5
5 - 9 74.9 25.1 82.8 17.2 83.3 16.7
≥10 56.4 43.6 89.6 10.4 81.6 18.4
Prescribed second-line treatment <0.001* (367) 0.461 (686) 0.359 (758)
TDF/3TC/LPV/r 63.5 36.5 84.6 15.4 76.8 23.2
AZT/3TC/LPV/r 80.6 19.4 82.4 17.6 79.7 20.3
Baseline CD4+ cell count at start 
of ART (cells/µL)
0.001* (367) 0.333 (585) 0.005* (647)
<100 84.2 15.8 85.0 15.0 80.1 19.9
101 - 200 75.9 24.1 80.2 19.8 82.5 17.5
201 - 350 75.0 25.0 78.4 21.6 78.2 21.9
351 - 500 64.0 36.0 91.3 8.7 51.7 48.3
>500 58.5 41.5 87.5 12.5 79.0 21.0
Most recent CD4+ cell count 
(cells/µL)
- <0.00*1 (327) 0.102 (337)
<100 - - 72.9 27.1 70.0 30.0
101 - 200 - - 76.0 24.0 82.7 17.3
201 - 350 - - 68.8 31.2 78.5 21.5
351 - 500 - - 85.5 14.5 82.6 17.4
>500 - - 95.4 4.6 88.5 11.5
Most recent VL (copies/mL) <0.001* (327) - <0.001* (711)
<1 000 68.6 31.4 - - 89.1 10.9
≥1 000 93.6 6.4 - - 59.8 40.2
VL = viral load; AIC = active in care; LTFU = lost to follow-up; CHC = community health centre; ART = antiretroviral therapy; TDF/3TC/LPV/r = tenofovir/lamivudine/lopinavir/ritonavir; 
AZT/3TC/LPV/r = zidovudine/lamivudine/lopinavir/ritonavir.
*Significant at p<0.05.
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Table 4. Logistical analysis of second-line patients for CD4+ cell count, VL and LTFU
OR (95% CI) p-value aOR (95% CI) p-value
Most recent CD4+ cell count >500 cells/µL
Gender 
Female 1.0 - 1.0 -
Male 0.53 (0.32 - 0.88) 0.013* 0.56 (0.33 - 0.98) 0.043*
New patients or transfers in
New 1.0 - 1.0 -
Transferred in 0.54 (0.33 - 0.88) 0.014* 0.71 (0.41 - 1.24) 0.229
Total duration of ART (years)
1 - 4 1.0 - 1.0 -
5 - 9 1.41 (0.82 - 2.40) 0.212 1.75 (0.96 - 3.18) 0.066
≥10 3.23 (1.51 - 6.91) 0.002* 2.72 (1.09 - 6.80) 0.031*
Prescribed second-line treatment
TDF/3TC/LPV/r 1.0 - 1.0 -
AZT/3TC/LPV/r 0.42 (0.26 - 0.69) 0.001* 0.63 (0.35 - 1.13) 0.118
Baseline CD4+ cell count at start of ART (cells/µL)
<100 1.0 - 1.0 -
101 - 200 1.69 (0.86 - 3.35) 0.130 1.46 (0.69 - 3.13) 0.322
201 - 350 1.78 (0.83 - 3.84) 0.141 2.05 (0.86 - 4.91) 0.106
351 - 500 3.01 (1.19 - 7.63) 0.020* 4.09 (1.23 - 13.56) 0.021*
>500 3.80 (1.96 - 7.39) <0.001* 3.22 (1.53 - 6.78) 0.002*
Most recent VL (copies/mL)
<1 000 1.0 - 1.0 -
≥1 000 0.15 (0.052 - 0.42) <0.001* 0.16 (0.056 - 0.48) 0.001*
VL suppression (≤1 000 copies/mL)
Age at ART switch (years)
<25 1.0 - 1.0 -
25 - 34 3.37 (1.26 - 8.98) 0.015* 3.18 (0.69 - 14.55) 0.137
35 - 49 3.81 (1.47 - 9.84) 0.006* 3.58 (0.81 - 15.82) 0.092
≥50 5.01 (1.59 - 15.79) 0.006* 3.87 (0.70 - 21.42) 0.121
Gender 
Female 1.0 - 1.0 -
Male 0.54 (0.36 - 0.81) 0.003* 0.63 (0.35 - 1.12) 0.116
New patients or transfers in
New 1.0 - 1.0 -
Transferred in 0.58 (0.38 - 0.89) 0.013* 0.86 (0.45 - 1.62) 0.635
Most recent CD4+ cell count (cells/µL)
<100 1.0 - 1.0 -
101 - 200 1.17 (0.47 - 2.92) 0.726 1.13 (0.44 - 2.91) 0.792
201 - 350 0.82 (0.37 - 1.81) 0.618 0.76 (0.33 - 1.72) 0.508
351 - 500 2.18 (0.85 - 5.66) 0.107 1.98 (0.75 - 5.24) 0.169
>500 7.71 (2.34 - 25.29) 0.001* 6.52 (1.94 - 21.85) 0.004*
Retention-in-care status – LTFU
Age at ART switch (years)
<25 1.0 - 1.0 -
25 - 34 0.57 (0.23 - 1.39) 0.216 0.53 (0.21 - 1.32) 0.175
35 - 49 0.49 (0.21 - 1.18) 0.114 0.48 (0.20 - 1.16) 0.103
≥50 0.36 (0.13 - 1.02) 0.053* 0.35 (0.12 - 1.01) 0.053*
Facility 
80 Albert Street Clinic Empty - Empty -
Charlotte Maxeke Hospital 1.0 - 1.0 -
Hillbrow CHC 0.27 (0.16 - 0.44) <0.001* 0.15 (0.07 - 0.33) <0.001*
Jeppe Clinic 0.38 (0.16 - 0.88) 0.024* 0.074 (0.009 - 0.59) 0.014*
Joubert Park Clinic 0.91 (0.39 - 2.14) 0.837 0.73 (0.23 - 2.35) 0.599
Malvern Clinic 0.26 (0.06 - 1.21) 0.086 0.45 (.09 - 2.32) 0.343
Rosettenville Clinic 0.78 (0.19 - 3.20) 0.734 0.82 (0.14 - 4.77) 0.826
South Rand Hospital 0.24 (0.12 - 0.47) <0.001* 0.25 (0.11 - 0.58) 0.001*
Continued ...
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historical first-line treatment (85% suppression rate) in Johannesburg 
subdistrict F.[20] The low CD4+ cell counts despite viral suppression 
could be indicative of slow CD4+ cell count recovery.[21] Just under 
three-quarters (72.4%) of our patients remained in care in the 
study sites over the reported period. The remaining 27.6% were no 
longer receiving care at the study sites (i.e. transferred out), were 
lost to follow-up or died. This is slightly lower than the reported 
retention rate of 78% in a first-line treatment cohort from inner-city 
Johannesburg.[22]
Recent VL suppression and recent CD4+ cell counts >500 cells/
µL were both correlated with a number of independent variables: 
males and transferred-in patients both had lower CD4+ cell counts 
and greater virological failure. Patients on TDF/3TC/LPV/r and 
patients with long durations of ART were correlated with CD4+ 
cell counts >500 cells/µL, but they did not show any statistically 
significant relationships with VL suppression. Age at ART switch did, 
however, show a strong stepwise correlation with virological failure, 
with patients aged 25 - 34 years, 35 - 50 years and >50 years each 
increasingly more likely to achieve viral suppression than patients 
aged <25 years.
There was also a correlation between age at ART switch and 
retention-in-care status, as patients >50 years of age were more 
likely to remain AIC. This is in keeping with recent findings from 
Kenya that older ART patients were more likely to remain in 
care than younger patients,[23] and older pooled Kenyan, Tanzania, 
Mozambican and Rwandan data.[24] Only three facilities, Hillbrow 
CHC, Jeppe Clinic and South Rand Hospital, were strongly associated 
with raised AIC rates. These findings are consistent with various 
reports released between 2014 and 2018 that described these 
three facilities, together with a few others in the Johannesburg 
metropolitan municipality, as providing high standards of care, 
their patients having comparatively short waiting times and good 
clinical support services (within facilities and from external health 
systems-strengthening support partners) in terms of implementation 
of clinical guidelines and leadership.[25-27] Ensuring quality of care, a 
sufficient space to provide ART services and shorter waiting times for 
ART patients have long been associated with patient retention and 
adherence to treatment. [28,29] Additionally, these findings demonstrate 
effective task shifting of ART services within the healthcare facilities 
and decentralisation of services between primary and higher levels 
of care (secondary and tertiary),[29-31] as well as out of the facility 
(e.g. Hillbrow CHC runs adherence clubs for stable, adherent ART 
patients). These three facilities could therefore be identified as 
providing models in terms of retention in care and adherence to 
treatment for other health facilities to follow.
Patients with baseline CD4+ cell counts at the start of ART of 
351 - 500 cells/µL were approximately three times more likely to be 
lost to follow-up than patients with CD4+ cell counts ≤100 cells/µL. 
It could be assumed that since patients with low CD4+ cell counts 
are at an increased risk of opportunistic infections and other HIV-
related complications, and of experiencing drug toxicity related 
to ART and HIV complications, they tend to remain in HIV care 
because they are ill and/or accessing care for multiple illnesses.[32-34] 
Patients who have been on ART for ≥5 years are ~50% less likely to 
be lost to follow-up than patients in their first 4 years of treatment. 
This evidence provides an opportunity for engaging patients from 
treatment initiation by providing additional support and counselling 
to ensure that they remain engaged throughout their treatment 
span. [35] Support and counselling benefits have been reported in first-
line treatment cohorts where similar retention-in-care patterns were 
identified.[35,36]
Mberi et al.[36] described a group receiving care from 2002 to 2012 
at a high-volume SA ART clinic. They reported 40% of the patients 
being LTFU within 12 months of starting ART, a slight subsequent 
decrease in retention, a sharp decline from year 5, and plateauing 
at year 8. Our group displayed better long-term retention, with 
the initial sharp decline only being seen at year 8 and plateauing 
halfway through year 12. Patient and programme monitoring, 
actively implementing adherence and retention programmes, better-
quality service delivery (described above) and possible improved 
accountability on the part of patients may have resulted in these 
slightly enhanced retention rates. The implication is that aggressively 
enforcing adherence and retention strategies will lead to better 
clinical outcomes and higher retention-in-care rates.
Study limitations
The analysis was performed for a limited number of facilities in one 
SA district and may not necessarily be generalisable to all the other 
districts. Owing to inconsistencies in data quality from TIER.Net it 
was difficult to accurately calculate time to second-line treatment 
from the exact time of treatment failure, as well as the time to 
suppression data. A standard VL result of 124 copies/mL is captured 
Table 4. (continued) Logistical analysis of second-line patients for CD4+ cell count, VL and LTFU
OR (95% CI) p-value aOR (95% CI) p-value
Total duration of ART (years)
1 - 4 1.0 - 1.0 -
5 - 9 0.47 (0.32 - 0.68) <0.001* 1.11 (0.60 - 2.04) 0.744
≥10 0.54 (0.30 - 0.96) 0.035* 1.13 (0.49 - 2.65) 0.765
Baseline CD4+ cell count at start of ART (cells/µL)
<101 1.0 - 1.0 -
101 - 200 0.86 (0.54 - 1.39) 0.544 0.70 (0.33 - 1.50) 0.362
201 - 350 1.15 (0.69 - 1.93) 0.585 1.14 (0.53 - 2.44) 0.734
351 - 500 3.13 (1.50 - 6.56) 0.002* 5.59 (1.89 - 16.58) 0.002*
>500 1.19 (0.73 - 1.94) 0.486 1.20 (0.59 - 2.43) 0.613
Most recent VL (copies/mL)
<1 000 1.0 - 1.0 -
≥1 000 3.63 (2.19 - 6.02) <0.001* 4.12 (2.32 - 7.29) <0.001*
VL = viral load; LTFU = lost to follow-up; OR = odds ratio: CI = confidence interval; aOR = adjusted OR; ART = antiretroviral therapy; TDF/3TC/LPV/r = tenofovir/lamivudine/lopinavir/
ritonavir; AZT/3TC/LPV/r = zidovudine/lamivudine/lopinavir/ritonavir ;VL = viral load; CHC = community health centre.
*Significant at p<0.05.
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into TIER.Net for patients who have a laboratory result reported as 
lower than detectable level (instead of actual values). This affects the 
calculated median and interquartile range values.
Conclusions
Our study described the long-term clinical outcomes of second-
line patients and identified demographic, laboratory and clinical 
factors that predicted virological failure in this group. The patients 
in this cohort did well virologically after switching to second-line 
therapy, although poorer outcomes remain an issue, especially among 
younger and male patients. The study also identified transfer of 
patients and patients on AZT/3TC/LPV/r as subdemographics that 
were likely to be associated with poorer laboratory outcomes. All 
these are easily identifiable factors that may trigger added adherence 
and support interventions including intensive patient engagement 
during the first few years of ART, targeted population-specific 
adherence support programmes, using mobile health solutions for 
patient communication and appointment reminders, prioritising 
male and youth-friendly ART adherence and retention initiatives, 
and implementing a single patient identifier to accurately monitor 
patient and programme outcomes.
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